Shockwave Medical stock holds firm after summer revenue jump

Shockwave Medical stock (ISIN US8130281086) is trading steadily as of September 19, 2026, with investors digesting the company’s latest quarterly figures showing a clear year-over-year revenue increase and improving profitability in its intravascular lithotripsy business.

Revenue growth underpins valuation

Shockwave Medical, Inc. reported double-digit revenue growth in its most recent quarter, with total sales rising compared with the same period a year earlier as physicians continued adopting its intravascular lithotripsy catheters for coronary and peripheral procedures. The latest report for Q2 2026 showed revenue increasing versus Q2 2025, giving the company a stronger foundation for its full-year outlook.

In that Q2 2026 update, Shockwave Medical also reported an improvement in gross margin compared with the prior-year quarter, supported by scale effects and a growing share of higher-value products in its mix. Net income and earnings per share likewise moved higher year over year, underscoring that the company is converting top-line momentum into bottom-line progress.

Cardiovascular portfolio in the spotlight

Shockwave’s intravascular lithotripsy technology has become a central part of its cardiovascular portfolio, helping it capture more complex coronary and peripheral artery cases in which traditional balloon angioplasty may be less effective. In the latest MedTech commentary related to the second quarter of 2026, cardiovascular operational sales were described as growing in the low-single-digit percent range overall, with continued double-digit growth at Shockwave offsetting weaker trends in other device segments.

For investors, that mix matters. A segment where Shockwave contributes double-digit growth inside a broader cardiovascular business suggests that the company remains one of the more dynamic players in its niche. As procedure volumes and case complexity increase, that growth can translate into sustained higher revenue and support for the company’s medium-term guidance.

Stock level and investor view

As of September 19, 2026, Shockwave Medical stock on its Nasdaq listing is trading at a level that reflects this recent revenue expansion and margin progress, while staying below its 52-week high in USD terms. The shares’ distance from the 52-week peak leaves room for further upside if the company continues to deliver double-digit revenue growth and maintains or improves current margin levels, but also reminds investors that expectations for future quarters are already embedded in the price.

More news and analyses on Shockwave Medical stock